Institutet för Hälso- och
Sjukvårdsekonomi
Box 2127
SE-220 02 Lund
Besök: Råbygatan 2
Tel: 046-32 91 00
ihe[at]ihe.se

Willis Michael
fil dr | projektledare

Arbetsområden

     •  Hälsoekonomiska utvärderingar
     •  Ekonomiska simuleringsmodeller 

Aktuella projekt:
Ekonomiska modellering
Kostnadseffektivitet av Diabetes Mellitus och obesitas interventioner
Betalningsvilja och Livskvalitet

Sjukdomsområde:
Diabetes Mellitus (Typ1 och Typ2)
Övervikt och Obesitas
Parkinsons Sjukdom
Schizofreni
Osteoporos
Cancer 



URVAL PRESENTATIONER

Traditional Risk Factors in T2DM Modeling: An Example Using Statins and the UKPDS 82 Outcomes Model”, Presented at Economics, simulation modelling & diabetes: The Mt Hood 2016 Challenge, St. Gallen, Switzerland, September 17-18, 2016. Johansen P, Willis M, Nilsson A, Asseburg C and Neslusan C

“The Role of Estimated Glomerular Filtration Rate (eGFR) in Cost-Effectiveness (CE) Analyses Using Canagliflozin (CANA) vs Sulfonylurea (SU) to Treat Type 2 Diabetes Mellitus (T2DM)”, Presented at ADA 76th Scientific Sessions, New Orleans, LA, USA, June 10-14, 2016, Neslusan C, Willis M, Johansen P, Schroeder M, Nilsson A, Chan E, Asseburg C, Schubert A

“Time Until Insulin Initiation for Canagliflozin (CANA) Versus Sitagliptin (SITA) in Dual Therapy and Triple Therapy for Type 2 Diabetes Mellitus (T2DM) in the UK”, Presented at ADA 76th Scientific Sessions, New Orleans, LA, USA, June 10-14, 2016, Schroeder M, Chan E, Willis M, Johansen P, Nilsson A, Schubert A, Neslusan C

“Time Until Insulin Initiation for Canagliflozin (CANA) Versus Dapagliflozin (DAPA) and Empagliflozin (EMPA) in Dual and Triple Therapy for Type 2 Diabetes Mellitus (T2DM) in the UK”, Presented at ISPOR 21st Annual International Meeting, Washington, WA, USA, May 21-25, 2016, Schroeder M, Chan E, Willis M, Johansen P, Nilsson A, Schubert A, Neslusan C

“Update of the Model Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM)”, Presented at ISPOR 21st Annual International Meeting, Washington, WA, USA, May 21-25, 2016, Asseburg C, Willis M, Johansen P, Nilsson A, Neslusan C, Schroeder M

“Threshold-Based Metrics May Not Value All Benefits of Improved HbA1c: Implications for Health Care Resource Allocation”, Presented at International Diabetes Federation - World Diabetes Congress, Vancouver, Canada, November 30 – December 4, 2015, Willis M, Neslusan C, Martin S, Johansen P, Asseburg C, O’Brien D

“The Cost-Effectiveness of Canagliflozin (CANA) Versus Dapagliflozin (DAPA) 10mg and Empagliflozin (EMPA) 25mg in Patients with Type 2 Diabetes Mellitus (T2DM) as Monotherapy in the United Kingdom”, Presented at ISPOR 18th Annual European Congress, Milan, Italy, November 7-11, 2015, Schroeder M, Johansen P, Willis M, Neslusan C.

"Impact of the Framingham Offspring Study (FOS) vs. Kaiser Permanente Northwest (KPNW) prediction equations for diabetes mellitus in economic modelling of T2DM". Presented at the 51st EASD Annual Meeting, Stockholm, Sweden, 14-18 September 2015, Asseburg C, Johansen P, Nilsson A, Willis M.

“The Effect of Treatment Intensification Assumptions on Estimates of Cost-Effectiveness in Type 2 Diabetes Mellitus”, Presented at ISPOR 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 16-20, 2015, Willis M, Johansen P, Neslusan C

“The Cost-Effectiveness of Canagliflozin versus Saxagliptin Among Older Individuals Living with Type 2 Diabetes Mellitus in Canada”, Presented at ISPOR 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 16-20, 2015, Teschemaker AR, Neslusan C, Sabapathy S, Yoong K, Johansen P, Willis M

“The Cost-Effectiveness of Canagliflozin versus Sitagliptin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea in a Canadian Setting”, Presented at ISPOR 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 16-20, 2015, Sabapathy S, Neslusan C, Yoong K, Teschemaker AR, Johansen P, Willis M

“Impact of Weight-related Utilities on the Cost-Effectiveness of Canagliflozin versus Sitagliptin as Third-line Therapy in Type 2 Diabetes Mellitus in a Canadian Setting Presented at ISPOR 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 16-20, 2015, Sabapathy S, Neslusan C, Yoong K, Teschemaker AR, Johansen P, Willis M

“Time until Insulin Initiation for Canagliflozin versus Dapagliflozin in Dual and Triple Therapy for Type 2 Diabetes Mellitus (T2DM) in Ireland”, Presented at ISPOR 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 16-20, 2015, Bacon T, Willis M, Johansen P, Neslusan C

“Impact on Schizophrenia Inpatient Resource Use Following Switch to Long-Acting Risperidone in Finland”, ISPOR 11th Annual European Congress, Athens, Greece, November 9-11, 2008. Mickael Löthgren, Christian Asseburg, Michael Willis, Niko Seppäla, Mika Hakala, Marianne Svensson and Ulf Persson.

“The Cost-Effectiveness of Canagliflozin (CANA) versus Sitagliptin (SITA) as Third-Line Therapy in the Treatment of Type 2 Diabetes Mellitus in the U.K.”, Presented at EASD 50th Annual Meeting, Stockholm, Sweden, September 15-19, 2014 Thompson G, Schroeder M, Neslusan C, Willis M, Johansen P, Teschemaker A

“The Cost-Effectiveness of the Early Insulin Use Treatment Pathway in the ADA/EASD Joint Consensus Algorithm for the Treatment of Type 2 Diabetes”, Poster presentation at the American Diabetes Association’s 68th Scientific Sessions, San Francisco, June 6-10, 2008. Michael Willis, Christian Asseburg, Cheryl Neslusan and Ulf Persson

“Impact of Switch to Long-Acting Risperdal Consta on Inpatient Resource Use for Treating Schizophrenia in Sweden”, 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders, Montreux, Switzerland, February 2-7, 2008. A.Berntsson, M. Willis, M. Svensson, U. Persson, B. Eriksson, M. Löthgren.

“Cost-Effectiveness of Strict ‘Get To Goal’ Treatment Directives in the Treatment of Younger Patients with Newly Diagnosed Type 2 Diabetes Mellitus, Presented at the 9th Annual ISPOR European Congress, Dublin, Ireland, October 20-23, 2007. Michael Willis, Christian Asseburg, Sixten Borg, Ulf Persson, and Cheryl Neslusan.

“Economic Modeling of a Chronic, Progressive Disease: The History, Challenges, and Lessons Learned from Diabetes Mellitus”, Panel session presentation at the International Health Economics Association’s 6th World Congress, Copenhagen, Denmark, July 8-11, 2007.

“Cost-Effectiveness of Sulfonylureas versus Metformin as First-Line Therapy in Newly Diagnosed Type 2 Diabetes”, Poster presentation at the 67th Scientific Sessions of the American Diabetes Association, Chicago, Illinois, June 22-26, 2007.

"The Cost-Effectiveness of Calcium and Vitamin D3 Supplementation for the Prevention of Osteoporotic Hip Fractures in Sweden" Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference, Cannes, France, November 10-13, 2001.

“The Health Economics of Treating CVD Risk Factors in Type 2 DM: Cost-Effectiveness Studies from UKPDS, 4S, and HOPE”, presentation for The Atherosclerotic Process: Inflammation, Diabetes, and Cost-Effectiveness, Malmö, Sweden, October 25, 2000.

“The Introduction of Crack Cocaine and the Rise in Urban Crime Rates”, presentation for the World Bank’s International Conference on Crime and Violence: Causes and Policy Responses, Bogota, Columbia, May 4-5, 2000.

“Economics of a New Treatment for Diabetic Foot Ulcers: The Cost-Effectiveness of Becaplermin in Sweden”, Poster presentation at European Association for the Study of Diabetes (EASD) Conference, Brussels, Belgium, September 28-October 2, 1999.

“Economics of a New Preventative Therapy for Osteoporotic Fractures: The Cost-Effectiveness of Livial in Sweden”, Paper presented at Nordic Health Economists’ Study Group, Reykjavik, Iceland, August 20-21, 1999.


Urval av publiceringar

Willis M, Asseburg C, Nilsson A, Johnsson K & Kartman B
Multivariate Prediction Equations for HbA1c Lowering, Weight Change, and Hypoglycemic Events Associated with Insulin Rescue Medication in Type 2 Diabetes Mellitus: Informing Economic Modelling
Value in Health, 2017 Mar; 20 (3): 357-371
Published online: December 2016


Willis M, Johansen P, Nilsson A and Asseburg C
Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM)
PharmacoEconomics 2017; 35(3): 375-96
Publicerad online: 12 november 2016 


Sabapathy S, Neslusan C, Yoong K, Teschemaker A, Johansen P & Willis M
Cost-effectiveness of Canagliflozin versus Sitagliptin when Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada
J Popul Ther Clin Pharmacol. 2016; 23(2): 151-168
July 15, 2016


Henriksson M, Jindal R, Sternhufvud C, Bergenheim K, Sörstadius E & Willis M
A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus
PharmacoEconomics, 2016.
Publicerad online 20 januari 2016.


Steen Carlsson K, Andersson E, Lundqvist A & Willis M
PÅVERKBARA KOSTNADER FÖR TYP 2-DIABETES ÅR 2020 OCH ÅR 2030 I SVERIGE. Prognoser med IHE Cohort Model of Type 2 Diabetes
Lund: IHE Rapport 2015:1

Neslusan C, Teschemaker A, Johansen P, Willis M, Valencia-Mendoza A & Puig A
Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metforminin Patients with Type2 Diabetes Mellitus in Mexico
Value in health regional issues 2015; 8C: 8-19
Publicerad online: 3 juni 2015
http://dx.doi.org/10.1016/j.vhri.2015.01.002


Lundqvist A, Steen Carlsson K, Johansen P, Andersson E & Willis M
Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk Equations
PLOS ONE 2014; 9(10): 1-12
Open access


Willis M, Erntoft S, Persson S, Norlin J, Persson U
Willingness-to-pay to access Ingenol Mebutate Gel for Actinic Keratosis Treatment in the U.S. Setting
Journal of Health Economics and Outcomes Research 2014; 2(1): 1-14

Willis M, Asseburg C & He J
Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM)
Journal of Medical Economics 2013; 16(8): 1007-1021
Read More: http://informahealthcare.com/doi/abs/10.3111/13696998.2013.809352


Asseburg C, Willis M, Löthgren M, Seppälä N, Hakala M & Persson U
Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection
Schizophrenia Research and Treatment. 2012; Volume 2012, Article ID 791468, 9 pages


Svensson M, Persson U, Willis M & Ödegaard K
Kostnadseffektivitet vid egna mätningar av blodglukos för diabetiker
Lund: IHE e-rapport 2010:2

Willis M, Svensson M, Löthgren M, Eriksson B, Berntsson A & Persson U
The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden
The European Journal of Health Economics, 2010; 11(6): 585-594 

Willis M, Persson U, Zoellner Y & Gradl B
Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden
Applied Health Economics and Health Policy 2010; 8(6): 377-86

“The Health Economics of Calcium and Vitamin D3 for the Prevention of Osteoporotic Hip Fractures in Sweden”, International Journal of Technology Assessment in Health Care 18 (Winter 2002): 861-877.

“Cost-Effectiveness of Tibolone in the Prevention of Osteoporotic Fractures After the Menopause”, Menopause Digest 14 (2002): 12-14.

”Cost-Effectiveness of Treating Deep Diabetic Foot Ulcers with Promogran in Four European Countries”, Journal of Wound Care 11 (February 2002): 70-74.

“Cost-Effectiveness of Becaplermin (Regranex) in the Treatment of Diabetic Foot Ulcers in Four European Countries", PharmacoEconomics 7 (2001): 767-778.

“A Cost-Effectiveness Model of Tibolone as Treatment for the Prevention of Osteoporotic Fractures in Postmenopausal Women in Sweden”, Clinical Drug Investigations 21 (2001): 115-127.

“The Cost-Effectiveness of Treating Diabetic Lower Extremity Ulcers with Becaplermin (Regranex): A Core Model with an Application using Swedish Cost Data”, Value in Health 3 (Supplement 1 2000): S39-S46.

“The Emergence of Crack Cocaine and Rises in Urban Crime”, The Review of Economics and Statistics 82 (November 2000): 519-529.

“The Cost-Effectiveness in the UK of Treating Lower Extremity Ulcers with Becaplermin Gel”, Journal of Medical Economics 3 (2000): 87-95.

“International Comparison of Health Care Systems Using Resource Profiles”, Bulletin of the World Health Organization 17 (Special Issue 2000): 175-185.

“Sjukhus i förändring: Jämförande studie av Uddevalla sjukhus, Princess Royal Hospital och Henry Ford Hospital (Hospitals in Change: A Comparison Study of Uddevalla Hospital, Princess Royal Hospital, and Henry Ford Hospital)”, IHE Working Paper 1999:5, 1999.

”Leading Firm Asymmetry as a Determinant of Advertising Intensity”, Review of Industrial Organization 13 (August 1998): 495-508. 

© IHE 2017